The effect of inactin on kidney mitochondrial function and production of reactive oxygen species

PLoS One. 2018 Nov 26;13(11):e0207728. doi: 10.1371/journal.pone.0207728. eCollection 2018.

Abstract

Inactin is a long lasting anesthetic agent commonly used in rat studies, but is also shown to exert physiological effects such as reducing renal blood flow, glomerular filtration rate and depressing tubular transport capacity. The effect of inactin on isolated kidney mitochondria is unknown and may be important when studying related topics in anaesthetized animals. The aim of this study was to determine whether inactin exerts effects on mitochondrial function and production of reactive oxygen species. Kidney mitochondrial function and production of reactive oxygen after acutely (5 min) or longer (1.5 hour) anesthetizing rats with inactin was evaluated using high-resolution respirometry. The results demonstrate that inactin significantly improves respiratory control ratio, inhibits complex I in the mitochondrial respiratory chain, reduce both unregulated proton leak and time dependently reduce the regulated proton leak via uncoupling protein-2 and adenine nucleotide translocase. Inactin also contributes to increased mitochondrial hydrogen peroxide production. In conclusion, inactin exerts persistent effects on mitochondrial function and these profound effects on mitochondrial function should to be considered when studying mitochondria isolated from animals anesthesized with inactin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Kidney / cytology*
  • Male
  • Mitochondria / drug effects*
  • Mitochondria / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism*
  • Thiopental / analogs & derivatives*
  • Thiopental / pharmacology
  • Time Factors

Substances

  • Reactive Oxygen Species
  • thiobutabarbital
  • Thiopental

Grants and funding

This work was funded by the Swedish Research Council, the Swedish Diabetes Foundation, Åke Wiberg Foundation, the Family Ernfors Foundation, the Swedish Society for Medical Research, the Lundbeck Foundation and the Danish Diabetes Academy supported by the Novo Nordisk Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.